The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Karlov V.A.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet

Gekht A.B.

N.I. Pirogov Russian State Medical University

Guzeva V.I.

Sankt-Peterburgskaia gosudarstvennaia pediatricheskaia meditsinskaia akademiia

Lipatova L.V.

Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva, Sankt-Peterburg

Bazilevich S.N.

Kafedra i klinika nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Mkrtchyan V.R.

Soloviev Scientific-Practical Psycho-Neurological Сenter, Moscow, Russia

Vlasov P.N.

GBUZ MO "Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii", Moskva

Zhidkova I.A.

Kafedra nervnykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Mukhin K.Iu.

Kafedra nervnykh bolezneĭ pediatricheskogo fakul'teta s kursom fakul'teta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Petrukhin A.S.

Kafedra nervnykh bolezneĭ pediatricheskogo fakul'teta s kursom fakul'teta usovershenstvovaniia vracheĭ Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Lebedeva A.V.

FGBU "Federal'nyĭ nauchnyĭ tsentr transplantologii i iskusstvennykh organov im. akad. V.I. Shumakova" Minzdrava Rossii, Moskva

Algorithms of mono- and polytherapy in clinical epileptology. Part 1. General principles of drug choice

Authors:

Karlov V.A., Gekht A.B., Guzeva V.I., Lipatova L.V., Bazilevich S.N., Mkrtchyan V.R., Vlasov P.N., Zhidkova I.A., Mukhin K.Iu., Petrukhin A.S., Lebedeva A.V.

More about the authors

Read: 2206 times


To cite this article:

Karlov VA, Gekht AB, Guzeva VI, et al. . Algorithms of mono- and polytherapy in clinical epileptology. Part 1. General principles of drug choice. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(6):109‑114. (In Russ.)
https://doi.org/10.17116/jnevro201611661109-114

Recommended articles:
Factors and features of the deve­lopment of epilepsy in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):18-27
Type 28 spinocerebellar ataxia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):61-64
Evolution of DEE-SWAS into photosensitive epilepsy in a patient with an ASH1L gene muta­tion. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):114-119
Epileptogenesis and functional labi­lity of the genome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):19-26

References:

  1. Covanis A, Guekht A, Li S, Mary Secco M, Shakir R, Perucca E. From global campaign to global commitment: The World Health Assembly’s Resolution on epilepsy. Epilepsia. **(*):1—7:2015. doi: 10.1111/epi.13192
  2. Rezoljucija VOZ. Global'noe bremja jepilepsii i neobhodimost' koordinirovannyh mer na urovne gosudarstv, v celjah vozdejstvija na ego posledstvija v oblasti zdravoohranenija, v social'noj sfere i oblasti informirovanija obshhestvennosti. Ssylka aktivna na aprel' 2015. Dostupno po: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_R20-ru.pdf (In Russ.).
  3. Callaghan B, Schlesinger M, Rodemer W, Pollard J, Hesdorffer D, Hauser WA, French J. Remission and relapse in a drug-resistant epilepsy population followed prospectively. Epilepsia. 201103;52(3):619-626.  doi: 10.1111/j.1528-1167.2010.02929.x
  4. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Jr JE, Forsgren L, French JA, Glunn M, Hesdorffer DC, Lee BI, Mathern GW, Moshé SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia. 201404;55(4):475-482.  doi: 10.1111/epi.12550
  5. Kwan P, Arzimonoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy. Consensus proposal by the ad hoc Tasc force of the ILAE Comission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-1077. doi: 10.1111/j.1528-1167.2009.02397.x
  6. Guekht A, Mitrokhina TV, Lebedeva AV, Dzugaeva FK, Milchakova LE, Lokshina OB, Feygina AA, Gusev EI. Factors influencing on quality of life in people with epilepsy. Seizure. 2007;16:128-133.  doi: 10.1016/j.seizure.2006.10.011
  7. Patsalos PN. Drug Interactions with the Newer Antiepileptic Drugs (AEDs). Part 1. Clin Pharmacokinet. 2013;52:927-966.  doi: 10.1007/s40262-013-0087-0 Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders. Clin Pharmacokinet. 2013;52:1045-1061. doi: 10.1007/s40262-013-0088-z
  8. Deckers C, Hekster YA, Keyser A, Van Lier HJJ, Meinardi H, Renier WO. Monotherapy vs Polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia. 2001;42(11):1387-1394. doi: 10.1046/j.1528-1157.2001.30800.x
  9. Baulac M. Rational conversion from antiepileptic polytherapy to monotherapy. Epileptic Disord. 2003;5(3):125-132. Ссылка активна на апрель 2016. Доступно по:http://www.jle.com/download/epd-261665-rational_conversion_from_antiepileptic_polytherapy_to_monotherapy_--VynWyX8AAQEAABiCohIAAAAI-a.pdf
  10. Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia. 2005;46:858-877.  doi: 10.1111/j.1528-1167.2005.54904.x
  11. Karlov V.A. Jepilepsija u detej i vzroslyh zhenshhin i muzhchin. Rukovodstvo dlja vrachej. M.: OAO «Izdatel'stvo «Medicina»; 2010.
  12. Perucca E. Pharmacoresistance in epilepsy. How should it be defined? CNS Drugs. 1998;10:171-179.  doi: 10.2165/00023210-199810030-00002
  13. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs-best practice guideline for therapeutic drug monitoring: a position paper by the subcomission on therapeutic drug monitoring, ILAE commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-1276. doi: 10.1111/j.1528-1167.2008.01561.x
  14. Perucca E, Dulac O, Shorvon S, Tomson T. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimization CNS. Drugs. 2001;15(8):609-621.  doi: 10.2165/00023210-200115080-00004
  15. Schmidt D, Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in relation to seizure frequency and type. Neurology. 1984;34:1252-5.  doi: http://dx.doi.org/10.1212/WNL.34.9.1252
  16. Schmidt D. Drug treatment of epilepsy: Options and limitations, Epilepsy & Behavior. 2009;15:56-65.  doi: 10.1016/j.yebeh.2009.02.030
  17. Kwan P, Brodie MJ. Combination Therapy in Epilepsy. When and What to Use. Drugs. 2006;66(14):1817-1829. doi: 10.2165/00003495-200666140-00004
  18. Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR, Jr and Bazil CW. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology. 2008;71;1527-1534. doi: 10.1212/01.wnl.0000334295.50403.4c
  19. Guberman AH, Besag FMC, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40:985-991. Accessed Apr 2016 by http://onlinelibrary.wiley.com/doi/10.1111/j.1528-1157.1999.tb00807.x/epdf doi: 10.1111/j.1528-1157.1999.tb00807.x
  20. Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Safety. 1998;18:281-296. Apr 2016. http://www.neurology.org/content/71/19/1527.long accessed doi: 10.2165/00002018-199818040-00004
  21. Bourgeois B. Reducing overtreatment. Epilepsy Res. 2002;52(1):53-60.  doi: 10.1016/S0920-1211(02)00185-7
  22. Panayiotopoulos CP, editor. Atlas of epilepsies. London: Springer-Verlag; 2010.
  23. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nature Reviews Neuroscience. 2004;5:553-564.  doi: 10.1038/nrn1430
  24. Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther. 2001;90:21-34.  doi: 10.1016/S0163-7258(01)00122-X
  25. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D'Giano C. ABC Transporters during Epilepsy and Mechanisms Underlying Multidrug Resistance in Refractory Epilepsy. Epilepsia. 2007;48(5):140-149.  doi: 10.1111/j.1528-1167.2007.01302.x
  26. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain. 2002;125(1):22-31.  doi: 10.1093/brain/awf002
  27. Bazilevich SN. Kriptogennaja jepilepsija u vzroslyh: «skrytye problemy strukturnogo blagopoluchija». Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova (Prilozhenie «Jepilepsija»). 2013;113:2:10-20. (In Russ.).
  28. Odinak MM, Bazilevich SN, Prokudin MJu, Skiba JaB. Farmakorezistentnost' pri fokal'nyh jepilepsijah u vzroslyh. Jepilepsija: fundamental'nye, klinicheskie i social'nye aspekty. Pod. red. Guseva EI, Geht AB. M.: APKIPPRO; 2013;874, 691-701. (In Russ.).
  29. Shorvon SD. Oxford Textbook of Epilepsy and Epileptic Seizures. Oxford University Press; 2010.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.